Published in Arthritis Rheum on December 19, 2011
Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis | NCT00443430
STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS (STARS) | NCT03728478
5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis. Rheumatol Int (2014) 1.41
Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2014) 1.11
Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol (2012) 1.06
Diagnosis and treatment of enthesitis-related arthritis. Adolesc Health Med Ther (2012) 0.95
Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J (2014) 0.93
Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis (2013) 0.88
Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases. Pharmacogenomics J (2014) 0.87
Whole blood gene expression profiling predicts therapeutic response at six months in patients with polyarticular juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 0.87
Self-reported pain and disease symptoms persist in juvenile idiopathic arthritis despite treatment advances: an electronic diary study. Arthritis Rheumatol (2014) 0.86
A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment. Ann Rheum Dis (2014) 0.86
Muscle strength, physical fitness and well-being in children and adolescents with juvenile idiopathic arthritis and the effect of an exercise programme: a randomized controlled trial. Pediatr Rheumatol Online J (2013) 0.86
Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches. Clin Epidemiol (2014) 0.82
A commentary on TREAT: the trial of early aggressive drug therapy in juvenile idiopathic arthritis. BMC Med (2012) 0.80
Dynamic tracking of functional gene modules in treated juvenile idiopathic arthritis. Genome Med (2015) 0.80
Contrast-enhanced MRI of the knee in children unaffected by clinical arthritis compared to clinically active juvenile idiopathic arthritis patients. Eur Radiol (2015) 0.80
Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol (2015) 0.79
Juvenile Idiopathic Arthritis: Diagnosis and Treatment. Rheumatol Ther (2016) 0.78
Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review. Pediatr Rheumatol Online J (2014) 0.78
Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration. Pediatr Rheumatol Online J (2016) 0.78
Patient-reported Outcomes across Categories of Juvenile Idiopathic Arthritis. J Rheumatol (2015) 0.77
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis. Ann Rheum Dis (2016) 0.77
Update on the treatment of juvenile idiopathic arthritis. Curr Allergy Asthma Rep (2013) 0.77
[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics]. Z Rheumatol (2014) 0.76
Whole blood expression profiling from the TREAT trial: insights for the pathogenesis of polyarticular juvenile idiopathic arthritis. Arthritis Res Ther (2016) 0.76
Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol (2013) 0.76
Genetic determinants for methotrexate response in juvenile idiopathic arthritis. Front Pharmacol (2015) 0.76
The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort. RMD Open (2015) 0.76
Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford) (2015) 0.76
Clinical utility of etanercept in the treatment of arthritides in children and adolescents. Adolesc Health Med Ther (2014) 0.75
Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther (2016) 0.75
Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. J Rheumatol (2017) 0.75
Prescription patterns for children with juvenile idiopathic arthritis in Michigan Medicaid: a comparison by prescriber type. Pediatr Rheumatol Online J (2014) 0.75
A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study. Pediatr Rheumatol Online J (2017) 0.75
X-linked agammaglobulinemia combined with juvenile idiopathic arthritis and invasive Klebsiella pneumoniae polyarticular septic arthritis. Clin Rheumatol (2014) 0.75
Epipolymorphisms associated with the clinical outcome of autoimmune arthritis affect CD4+ T cell activation pathways. Proc Natl Acad Sci U S A (2016) 0.75
Predictors of juvenile idiopathic arthritis course. Reumatologia (2015) 0.75
Wait times to rheumatology care for patients with rheumatic diseases: a data linkage study of primary care electronic medical records and administrative data. CMAJ Open (2016) 0.75
Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children and young people with Juvenile Idiopathic Arthritis: results from the childhood arthritis prospective Study. Rheumatology (Oxford) (2016) 0.75
Assessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists. Pediatr Rheumatol Online J (2013) 0.75
Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. RMD Open (2016) 0.75
Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure. Clin Rheumatol (2013) 0.75
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol (2004) 14.06
Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum (1997) 5.57
Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum (2002) 4.77
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med (2000) 4.76
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum (2000) 2.92
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol (2004) 2.91
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum (2008) 2.56
Chronic childhood disorders: prevalence and impact. Pediatr Clin North Am (1984) 2.07
Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum (2002) 1.75
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 1.65
Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum (2003) 1.56
Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum (2005) 1.56
Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross-sectional long-term followup study. Arthritis Rheum (1999) 1.52
Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol (2004) 1.35
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol (2003) 1.28
Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis (2011) 1.27
Early rheumatoid arthritis: a medical emergency? Am J Med (2001) 1.02
Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum (2003) 1.02
Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis. J Rheumatol (2005) 0.95
Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Ann Rheum Dis (2010) 0.93
Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2010) 0.91
An association between the acute phase response and patterns of antigen induced T cell proliferation in juvenile idiopathic arthritis. Arthritis Res Ther (2003) 0.86
Remission in juvenile idiopathic arthritis: current facts. Curr Rheumatol Rep (2010) 0.86
Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Pediatr Clin North Am (2005) 0.85
Rheumatic diseases of childhood. Rheum Dis Clin North Am (1990) 0.81
Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study. Ann Rheum Dis (2005) 0.81
Managing the health effects of climate change: Lancet and University College London Institute for Global Health Commission. Lancet (2009) 12.03
Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med (2007) 6.22
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum (2002) 4.98
Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med (2014) 4.70
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 4.15
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science (2003) 3.60
Biomechanical measures during landing and postural stability predict second anterior cruciate ligament injury after anterior cruciate ligament reconstruction and return to sport. Am J Sports Med (2010) 3.36
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2007) 3.32
The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum (2002) 3.27
The PedsQL 4.0 Generic Core Scales: sensitivity, responsiveness, and impact on clinical decision-making. J Behav Med (2002) 3.23
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 3.14
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol (2004) 2.91
Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol (2011) 2.65
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum (2008) 2.56
The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum (2007) 2.56
The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum (2005) 2.55
Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol (2008) 2.36
Arsenic exposure from drinking water and birth weight. Epidemiology (2003) 2.32
Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol (2008) 2.23
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2012) 2.21
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) (2003) 2.18
Pubertal correlates in black and white girls. J Pediatr (2006) 2.12
Mothers' intention for their daughters and themselves to receive the human papillomavirus vaccine: a national study of nurses. Pediatrics (2009) 2.10
Fibroblastic rheumatism: case report and review of the literature. Pediatr Dermatol (2002) 2.05
Sexual behaviour of adolescents in Nigeria: cross sectional survey of secondary school students. BMJ (2003) 2.02
Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum (2007) 2.00
Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health (2005) 2.00
Patterns of colorectal cancer incidence, risk factors, and screening in Kentucky. South Med J (2004) 1.94
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Homeobox protein Hop functions in the adult cardiac conduction system. Circ Res (2005) 1.93
A multilevel analysis of the relation of socioeconomic status to adolescent depressive symptoms: does school context matter? J Pediatr (2003) 1.90
The public health impact of socioeconomic status on adolescent depression and obesity. Am J Public Health (2003) 1.90
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) (2012) 1.84
The PedsQL Multidimensional Fatigue Scale in pediatric rheumatology: reliability and validity. J Rheumatol (2004) 1.80
Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 1.79
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum (2011) 1.79
An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int (2004) 1.76
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum (2005) 1.75
Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr (2007) 1.75
Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol (2003) 1.75
Socioeconomic status, depressive symptoms, and adolescent substance use. Arch Pediatr Adolesc Med (2002) 1.74
Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol (2011) 1.72
A structural and functional ground plan for neurons in the hindbrain of zebrafish. Proc Natl Acad Sci U S A (2011) 1.72
Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. J Rheumatol (2008) 1.71
Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr (2006) 1.71
Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis. J Rheumatol (2012) 1.70
Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trial. Arthritis Rheum (2012) 1.68
Perceived socioeconomic status: a new type of identity that influences adolescents' self-rated health. J Adolesc Health (2007) 1.68
International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum (2004) 1.66
Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum (2007) 1.66
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 1.65
Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) (2010) 1.65
Comparison of teenagers' early same-sex and heterosexual behavior: UK data from the SHARE and RIPPLE studies. J Adolesc Health (2010) 1.63
Patterns and determinants of physical activity in U.S. adolescents. J Adolesc Health (2008) 1.63
Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol (2002) 1.62
A comparison of reviewers selected by editors and reviewers suggested by authors. J Pediatr (2007) 1.62
Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A (2005) 1.60
Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet (2011) 1.60
Parents' information needs in tumor necrosis factor-α inhibitor treatment decisions. J Pediatr Gastroenterol Nutr (2013) 1.59
Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum (2006) 1.59
Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol (2012) 1.59
Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum (2009) 1.56
Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum (2005) 1.56
Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum (2009) 1.56